Navigation Links
China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Date:1/29/2008

-- The Approval Creates New Growth Opportunities for the Company -- Potentially Denotes a Positive Sign Related to the SFDA Drug Approval

Process

NEW YORK and HAIKOU, China, Jan. 29 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic Bumetanide injection which is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome by inducing dieresis.

Bumetanide is internationally recognized as one of the most effective diuretics and widely prescribed for cardiovascular diseases, kidney diseases, respiratory diseases, neurological diseases, and surgeries. It has replaced Furosemidum and other diuretic medications on the market because of its efficiency and safety. Bumetanide is on China's National Medical Reimbursement Insurance List thus allowing insured patients to receive reimbursement for the costs of injections. In China, medium size hospitals dispense on average 8,000 doses of Bumetanide per month.

"We are very pleased that we received approval of Bumetanide from the Chinese SFDA, a very important and positive milestone for our business which further diversifies and complements our core product portfolio," Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., commented. "We believe this favorable decision by the SFDA is a positive sign that the SFDA new drug approval process is coming back online. For this reason, we are optimistic that the additional drugs that are currently in our development pipeline for SFDA approval will be able to move through this process toward commercialization."

"Additionally, we are well positioned to take advantage of this new growth opportunity. This approval will enable China Pharma to immediately leverage our production capacity and extensive distribution network covering 30 provinces to start production and marketing of this new drug. We expect to begin Bumetanide production and recording of revenues in March 2008. We currently maintain the capacity to produce approximately $2 million of this product annually," concluded Ms. Li.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

Safe Harbor Statement:

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Sophia Yu

China Pharma Holdings, Inc.

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

Alan Sheinwald

HC International, Inc.

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008
2. China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Womens Health Issues
3. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
4. Knee Implant Market Booming in China
5. Chinas biotech industry: An Asian dragon is growing
6. Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China
7. China Sky One Medical Appoints Independent Auditor
8. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
9. MM2 Group Establishes New Venture for Sofgel Manufacture in China
10. China Shenghuo Pharmaceutical Holdings, Inc. to Launch 12Ways(R) Advertisement on CCTV in January 2008
11. Chinas Anti-Aging Revolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing the ... the summer months provide more than warmer temperatures that are perfect for BBQ’s and ... from direct exposure to the sun. When it comes to the security of homes ...
(Date:6/23/2017)... ... June 23, 2017 , ... The ... launch of Care Management Alerts and Dashboards, an innovative new service enabling healthcare ... , RIQI’s Care Management Alerts and Dashboards provide near real-time data about patients ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... ... show evidence that carotenoids and antioxidants derived either from the diet or from supplements ... often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, changes ... of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... surgeon practicing in Newburgh, New York, has recently begun offering three new minimally ... offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
(Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology: